Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

被引：14

作者：

Tone, Mari ^{[1
]}

Izumo, Takehiro ^{[1
]}

Awano, Nobuyasu ^{[1
]}

Kuse, Naoyuki ^{[1
]}

Inomata, Minoru ^{[1
]}

Jo, Tatsunori ^{[1
]}

Yoshimura, Hanako ^{[1
]}

Miyamoto, Shingo ^{[2
]}

Kunitoh, Hideo ^{[2
]}

机构：

[1] Japanese Red Cross Med Ctr, Dept Resp Med, Shibuya Ku, Tokyo, Japan

[2] Japanese Red Cross Med Ctr, Dept Med Oncol, Shibuya Ku, Tokyo, Japan

来源：

LUNG CANCER MANAGEMENT | 2019年 / 8卷 / 02期

关键词：

immune checkpoint inhibitor; NSCLC; salvage chemotherapy; RANDOMIZED PHASE-III; RESPONSE RATES; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; VINORELBINE; CARBOPLATIN; TRIAL; CELLS;

D O I：

10.2217/lmt-2019-0001

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.

引用

页数：7

共 50 条

[1] Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer
Kuo, Chih-Hsi Scott
Wang, Chin-Chou
Huang, Yu-Chen
Pavlidis, Stelios
Liu, Chien-Ying
Ko, How-Wen
Chung, Fu-Tsai
Lin, Tin-Yu
Wang, Chih-Liang
Guo, Yi-Ke
Yang, Cheng-Ta
THORACIC CANCER, 2019, 10 (05) : 1158 - 1166
[2] Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Onoi, Keisuke
Chihara, Yusuke
Uchino, Junji
Shimamoto, Takayuki
Morimoto, Yoshie
Iwasaku, Masahiro
Kaneko, Yoshiko
Yamada, Tadaaki
Takayama, Koichi
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
[3] Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
Liu, Wei
Zhang, Lei
Xiu, Zhiming
Guo, Jian
Wang, Liye
Zhou, Yue
Jiao, Yang
Sun, Meiyan
Cai, Jianhui
ONCOTARGETS AND THERAPY, 2020, 13 : 7229 - 7241
[4] Immune Checkpoint Inhibitors in Lung Cancer and Melanoma
Madden, Kathleen
Kasler, Mary Kate
SEMINARS IN ONCOLOGY NURSING, 2019, 35 (05)
[5] Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment
Glode, Ashley E.
May, Megan B.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (09) : 769 - 780
[6] Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
Lee, Jiyun
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung-Ju
JOURNAL OF THORACIC DISEASE, 2020, 12 (07) : 3796 - 3803
[7] Immune checkpoint inhibitors in lung cancer: past, present and future
Seetharamu, Nagashree
Budman, Daniel R.
Sullivan, Kevin M.
FUTURE ONCOLOGY, 2016, 12 (09) : 1151 - 1163
[8] Safety and Efficacy of Salvage Surgery after Treatment With Immune-Checkpoint Adjuvant Inhibitors for Advanced Non-Small Cell Lung Cancer: A Multicentric Study
Schiavon, Marco
Cannone, Giorgio
Bertolaccini, Luca
Gallina, Filippo Tommaso
Pezzuto, Federica
Lorenzoni, Giulia
Facciolo, Francesco
Spaggiari, Lorenzo
Calabrese, Fiorella
Rea, Federico
Pasello, Giulia
JOURNAL OF SURGICAL ONCOLOGY, 2024,
[9] Immune checkpoint inhibitors in lung cancer
Koleczko, S.
Wolf, J.
INTERNIST, 2020, 61 (07): : 676 - 681
[10] Current advances in the treatment of lung cancer with immune checkpoint inhibitors
Lee, Gyeong-Won
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (05): : 333 - 341

← 1 2 3 4 5 →